TrovaGene Inc. (TROV)

0.31
0.00 0.64
NASDAQ : Health Technology
Prev Close 0.31
Open 0.31
Day Low/High 0.31 / 0.32
52 Wk Low/High 0.23 / 2.14
Volume 723.93K
Avg Volume 1.93M
Exchange NASDAQ
Shares Outstanding 52.79M
Market Cap 17.46M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Trovagene Announces Initiation Of UNITE Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Trovagene Announces Initiation Of UNITE Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PCM-075, Trovagene's highly-selective Polo-like Kinase 1 (PLK1) inhibitor may extend patient response to therapy when used in combination with Zytiga® (abiraterone) in mCRPC

Trovagene Announces Activation Of Second Clinical Trial Site In Phase 1b/2 Acute Myeloid Leukemia (AML) Trial For PCM-075

Trovagene Announces Activation Of Second Clinical Trial Site In Phase 1b/2 Acute Myeloid Leukemia (AML) Trial For PCM-075

Activation of second trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and preliminary anti-leukemic activity

Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of PCM-075 In Combination With Zytiga® For Metastatic Castration-Resistant Prostate Cancer

Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of PCM-075 In Combination With Zytiga® For Metastatic Castration-Resistant Prostate Cancer

PCM-075, Trovagene's Polo-like Kinase 1 (PLK1) inhibitor enhances activity of abiraterone in mCRPC tumor cells and may represent a novel combination treatment option in mCRPC

Trovagene Presents Data Showing Sensitivity Of Triple Negative Breast Cancer (TNBC) Cell Lines To PCM-075 And Synergy With Zytiga® At San Antonio Breast Cancer Symposium (SABCS)

Trovagene Presents Data Showing Sensitivity Of Triple Negative Breast Cancer (TNBC) Cell Lines To PCM-075 And Synergy With Zytiga® At San Antonio Breast Cancer Symposium (SABCS)

Targeted treatment with highly selective Polo-like Kinase 1 inhibitor, PCM-075, may represent a new option in TNBC, particularly in combination with other abiraterone acetate

Trovagene Announces Activation Of First Clinical Trial Site In Phase 1b/2 Acute Myeloid Leukemia (AML) Trial For PCM-075

Trovagene Announces Activation Of First Clinical Trial Site In Phase 1b/2 Acute Myeloid Leukemia (AML) Trial For PCM-075

Activation of first trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and preliminary anti-leukemic activity

Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy With Zytiga® (abiraterone Acetate) In Castration Resistant Prostate Cancer Tumor Cells

Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy With Zytiga® (abiraterone Acetate) In Castration Resistant Prostate Cancer Tumor Cells

PCM-075 enhances activity of abiraterone in mCRPC tumors cells and may represent a novel treatment option to extend the benefit of anti-androgen therapy

Trovagene Strengthens Board Of Directors With Appointment Of Oncology Development Veteran Dr. Athena Countouriotis

Trovagene Strengthens Board Of Directors With Appointment Of Oncology Development Veteran Dr. Athena Countouriotis

Dr. Athena Countouriotis joins Trovagene's Board of Directors, bringing significant experience in oncology clinical development and orphan indications

Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy With A HDAC Inhibitor In Non-Hodgkin Lymphoma Cell Lines

Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy With A HDAC Inhibitor In Non-Hodgkin Lymphoma Cell Lines

Additionally, Trovagene announces PCM-075 synergy in combination with more than ten chemo and targeted therapeutics across a broad range of solid tumor and hematologic malignancies

Trovagene's PLK1 Inhibitor PCM-075, In Preclinical AML Data, Significantly Enhances The Efficacy Of A FLT3 Inhibitor In Combination Therapy

Trovagene's PLK1 Inhibitor PCM-075, In Preclinical AML Data, Significantly Enhances The Efficacy Of A FLT3 Inhibitor In Combination Therapy

Human AML xenograft with FLT3 mutation shows PCM-075 in combination with Quizartinib resulted in 96% tumor growth inhibition with tumor regression

Trovagene Announces FDA Approval Of IND For Phase 1b/2 Trial Of PCM-075 In Patients With Acute Myeloid Leukemia

Trovagene Announces FDA Approval Of IND For Phase 1b/2 Trial Of PCM-075 In Patients With Acute Myeloid Leukemia

PCM-075, in combination with decitabine, in patients with Acute Myeloid Leukemia (AML) for exploration of the safety, tolerability, dose and scheduling, and antitumor activity

Trovagene Announces Peer-Reviewed Publication Of First-in-Human Phase 1 Trial Results With PCM-075, Its Polo-like Kinase 1 (PLK1) Inhibitor

Trovagene Announces Peer-Reviewed Publication Of First-in-Human Phase 1 Trial Results With PCM-075, Its Polo-like Kinase 1 (PLK1) Inhibitor

Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075's potential as safe and effective treatment for solid tumor and hematological malignancies

Short Interest Expands By 14.2% For TROV

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 442,930 share increase in total short interest for TrovaGene Inc , to 3,567,833, an increase of 14.17% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TheStreet Quant Rating: D- (Sell)